https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
Furthermore, we found a similar reduction of MMSC characteristics by lycorine in BTZ-resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, lycorine is a potential therapeutic strategy for MM treatments. © 2020 British Society for Haematology and John Wiley Sons Ltd.OBJECTIVE Through international collaboration, we evaluated the phenotypic aspects of a
Like
Comment
Share
